Purpose. To test the antitumor activity of magnetic fluid (MF) on the basis of substituted lanthanum-strontium manganite nanoparticles combined with alternating magnetic field (AMF) in experiments with transplanted tumors. Materials and Methods. MF with a size of nanoparticles of 30–40？nm in aqueous agarose solution was investigated. The ability of MF to heat tumor under AMF (300？kHz, 7.7？kA/m) was tested in vivo with rodent tumors (Guerin carcinoma, Walker-256 carcinosarcoma, and Lewis lung carcinoma (3LL)). Results. Single administration of MF into the tumor at a dose of 150？mg/kg (rats) or 200？mg/kg (mice) followed by AMF within 20–30？min (treatment was repeated 3-4-fold) has resulted in the complete regression of tumor in the 35% of rats and 57% of mice. Administration of MF alone or action of AMF alone has not resulted in tumor growth inhibition. The chemomodifying effect of nanohyperthermia was determined, in particular for cisplatinum: thermal enhancement ratio was 2.0. It was also observed that nanohyperthermia has resulted in the absence of 3LL metastases in 43% of mice. Conclusions. MF on the basis of lanthanum-strontium manganite may be considered as an effective inductor of tumor local hyperthermia. 1. Introduction The hyperthermia (HT) of human malignant tumor is used in the combined antitumor therapy and demonstrates significant modifying effect that results in the improvement of patients’ survival [1–3]. At the same time technical problems of microwave HT, that is, a main method for tumor heating, do not allow receiving the maximal homogenous heating of tumor and cause the definite side effects. One of the approaches to resolve this problem is a creation of magnetic fluids (MF) on the basis of ferromagnetic nanoparticles which are able to heat the tumor tissue under external alternating magnetic field (AMF), that was shown in the pioneer work of Jordan et al. [4]. The use of nanosized magnetic particles, which are able to generate heat under AMF, offers much extensive scope for the use of HT in the therapy of malignant tumors [5–7]. The effective application of magnetic nanoparticles was shown in the combination with AMF in the experiment with transplanted tumors both in the regime of thermal ablation and thermochemotherapy [8, 9]. The nanoparticles of ferromagnetic materials have to meet various requirements; in particular, they must be slightly agglomerated, small sized, single-domained, easily excretable from the body, able to demonstrate high values of the SLP (specific loss power), and able to exhibit superparamagnetic properties
References
[1]
J. van der Zee, Z. Vujaskovic, M. Kondo, and T. Sugahara, “The Kadota Fund International Forum 2004—clinical group consensus,” International Journal of Hyperthermia, vol. 24, no. 2, pp. 111–122, 2008.
[2]
R. D. Issels, L. H. Lindner, J. Verweij et al., “Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study,” The Lancet Oncology, vol. 11, no. 6, pp. 561–570, 2010.
[3]
P. Kaur, M. D. Hurwitz, S. Krishnan, and A. Asea, “Combined hyperthermia and radiotherapy for the treatment of cancer,” Cancers, vol. 3, no. 4, pp. 3799–3823, 2011.
[4]
A. Jordan, P. Wust, H. F？hling, W. John, A. Hinz, and R. Felix, “Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia,” International Journal of Hyperthermia, vol. 9, no. 1, pp. 51–68, 1993.
[5]
B. Thiesen and A. Jordan, “Clinical applications of magnetic nanoparticles for hyperthermia,” International Journal of Hyperthermia, vol. 24, no. 6, pp. 467–474, 2008.
[6]
G. Bellizzi and O. M. Bucci, “On the optimal choice of the exposure conditions and the nanoparticle features in magnetic nanoparticle hyperthermia,” International Journal of Hyperthermia, vol. 26, no. 4, pp. 389–403, 2010.
[7]
W. C. Zamboni, V. Torchilin, A. K. Patri et al., “Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance,” Clinical Cancer Research, vol. 18, no. 12, pp. 3229–3241, 2012.
[8]
I. Hilger, R. Hiergeist, R. Hergt, K. Winnefeld, H. Schubert, and W. A. Kaiser, “Thermal ablation of tumors using magnetic nanoparticles: an in vivo feasibility study,” Investigative Radiology, vol. 37, no. 10, pp. 580–586, 2002.
[9]
S. Laurent, S. Dutz, U. O. H？feli, and M. Mahmoudi, “Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles,” Advances in Colloid and Interface Science, vol. 166, no. 1-2, pp. 8–23, 2011.
[10]
A. P. Khandhar, R. M. Ferguson, J. A. Simon, and K. M. Krishnan, “Enhancing cancer therapeutics using size-optimized magnetic fluid hyperthermia,” Journal of Applied Physics, vol. 111, no. 7, Article ID 07B306, 2012.
[11]
K. Maier-Hauff, F. Ulrich, D. Nestler et al., “Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme,” Journal of Neuro-Oncology, vol. 103, no. 2, pp. 317–324, 2011.
[12]
M. Johannsen, B. Thiesen, P. Wust, and A. Jordan, “Magnetic nanoparticle hyperthermia for prostate cancer,” International Journal of Hyperthermia, vol. 26, no. 8, pp. 790–795, 2010.
[13]
Q. Zhao, L. Wang, R. Cheng et al., “Magnetic nanoparticle-based hyperthermia for head & neck cancer in mouse models,” Theranostics, vol. 2, no. 1, pp. 113–121, 2012.
[14]
K. Hayashi, M. Nakamura, W. Sakamoto et al., “Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment,” Theranostics, vol. 3, no. 6, pp. 366–376, 2013.
[15]
E. Pollert, O. Kaman, P. Veverka, et al., “Core-shell La1-x Srx MnO3 nanoparticles as colloidal mediators for magnetic fluid hyperthermia,” Philosophical Transactions of the Royal Society A, vol. 368, no. 1927, pp. 4389–4405, 2010.
[16]
S. O. Solopan, O. I. V'Yunov, A. G. Belous, T. I. Polek, and A. I. Tovstolytkin, “Effect of nanoparticles agglomeration on electrical properties of La1-xAxMnO3 (A = Sr, Ba) nanopowder and ceramic solid solutions,” Solid State Sciences, vol. 14, no. 4, pp. 501–505, 2012.
[17]
S. Vasseur, E. Duguet, J. Portier et al., “Lanthanum manganese perovskite nanoparticles as possible in vivo mediators for magnetic hyperthermia,” Journal of Magnetism and Magnetic Materials, vol. 302, no. 2, pp. 315–320, 2006.
[18]
E. Pollert, K. Kní？ek, M. Mary？ko, P. Ka？par, S. Vasseur, and E. Duguet, “New Tc-tuned magnetic nanoparticles for self-controlled hyperthermia,” Journal of Magnetism and Magnetic Materials, vol. 316, no. 2, pp. 122–125, 2007.
[19]
A. A. Kuznetsov, O. A. Shlyakhtin, N. A. Brusentsov, and O. A. Kuznetsov, “‘Smart’ mediators for self-controlled inductive heating,” European Cells and Materials, vol. 3, supplement 2, pp. 75–77, 2002.
[20]
V. Uskokovi？, A. Ko？ak, and M. Drofenik, “Preparation of silica-coated lanthanum-strontium manganite particles with designable curie point, for application in hyperthermia treatments,” International Journal of Applied Ceramic Technology, vol. 3, no. 2, pp. 134–143, 2006.
[21]
E. Natividad, M. Castro, G. Goglio et al., “New insights into the heating mechanisms and self-regulating abilities of manganite perovskite nanoparticles suitable for magnetic fluid hyperthermia,” Nanoscale, vol. 4, no. 13, pp. 3954–3962, 2012.
[22]
S. Sakka, Ed., Handbook of Sol-Gel Science and Technology: Processing, Characterization and Application, Kluwer Academic Publishers, New York, NY, USA, 2005.
[23]
A. G. Belous, O. I. V'yunov, E. V. Pashkova, O. Z. Yanchevskii, A. I. Tovstolytkin, and A. M. Pogorelyi, “Effects of chemical composition and sintering temperature on the structure of La1-xSrxMnO3±γ solid solutions,” Inorganic Materials, vol. 39, no. 2, pp. 161–170, 2003.
[24]
S. Solopan, A. Belous, A. Yelenich et al., “Nanohyperthermia of malignant tumors. I. Lanthanum-strontium manganite magnetic fluid as potential inducer of tumor hyperthermia,” Experimental Oncology, vol. 33, no. 3, pp. 130–135, 2011.
[25]
L. Bubnovskaya, A. Belous, A. Solopan et al., “Nanohyperthermia of malignant tumors. II. In vivo tumor heating with manganese perovskite nanoparticles,” Experimental Oncology, vol. 34, no. 4, pp. 336–339, 2012.
[26]
R. D. Issels, “Hyperthermia adds to chemotherapy,” European Journal of Cancer, vol. 44, no. 17, pp. 2546–2554, 2008.
[27]
A. Belous, S. Solopan, A. Yelenich, L. Bubnovskaya, S. Osinsky, and L. Bovkun, “Synthesis and properties of ferromagnetic nanoparticles for potential biomedical application,” in Proceedings of the 34th IEEE International Scientific Conference on “Electronics and Nanotechnology ” (ELNANO '14), Conference Proceedings, pp. 245–249, Kyiv, Ukraine, April 2014.
[28]
A. Belous, S. Solopan, A. Yelenich, L. Bubnovskaya, and S. Osinsky, “Nanoparticles of ferromagnetic materials and possibilities of their application in the hyperthermia of malignant tumors,” in Proceedings of the IEEE 33rd International Scientific Conference Electronics and Nanotechnology (ELNANO '13), pp. 280–284, Kyiv, Ukraine, April 2013.
[29]
S. Osinsky, L. Bubnovskaja, and A. Gusev, “Procedures for improving therapeutic gain,” Advances in Experimental Medicine and Biology, vol. 267, pp. 251–270, 1990.
